Combining S-1 and Gemcitabine for Pancreatic Cancer
Author Information
Author(s): Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H, Saisho H
Primary Institution: Chiba University
Hypothesis
Can the combination of S-1 and gemcitabine improve treatment outcomes in metastatic pancreatic cancer patients?
Conclusion
The combination of gemcitabine and S-1 is well tolerated and shows a high response rate in patients with metastatic pancreatic cancer.
Supporting Evidence
- 16 patients had objective responses, including one complete response and 15 partial responses.
- The overall response rate was 48%.
- Median survival time was 12.5 months.
- 1-year survival rate was 54%.
- Grade 3–4 toxicities included neutropenia (55%) and leucopenia (33%).
Takeaway
Doctors tested a new medicine called S-1 with another medicine called gemcitabine to help people with a serious type of cancer, and it worked pretty well.
Methodology
Patients received S-1 orally for 14 days and gemcitabine on specific days, with cycles repeated every 21 days.
Potential Biases
Potential selection bias due to the non-randomized nature of the trial.
Limitations
The study was limited to a small sample size and lacked a control group.
Participant Demographics
Median age was 61 years, with 64% male and 36% female participants.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI, 33–65
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website